全文获取类型
收费全文 | 7280篇 |
免费 | 381篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 52篇 |
儿科学 | 278篇 |
妇产科学 | 227篇 |
基础医学 | 756篇 |
口腔科学 | 24篇 |
临床医学 | 1090篇 |
内科学 | 1249篇 |
皮肤病学 | 117篇 |
神经病学 | 708篇 |
特种医学 | 170篇 |
外科学 | 760篇 |
综合类 | 65篇 |
一般理论 | 20篇 |
预防医学 | 994篇 |
眼科学 | 160篇 |
药学 | 369篇 |
中国医学 | 4篇 |
肿瘤学 | 626篇 |
出版年
2024年 | 6篇 |
2023年 | 40篇 |
2022年 | 65篇 |
2021年 | 158篇 |
2020年 | 86篇 |
2019年 | 182篇 |
2018年 | 215篇 |
2017年 | 156篇 |
2016年 | 157篇 |
2015年 | 136篇 |
2014年 | 233篇 |
2013年 | 387篇 |
2012年 | 582篇 |
2011年 | 622篇 |
2010年 | 346篇 |
2009年 | 300篇 |
2008年 | 505篇 |
2007年 | 545篇 |
2006年 | 526篇 |
2005年 | 517篇 |
2004年 | 465篇 |
2003年 | 445篇 |
2002年 | 426篇 |
2001年 | 57篇 |
2000年 | 44篇 |
1999年 | 56篇 |
1998年 | 63篇 |
1997年 | 51篇 |
1996年 | 37篇 |
1995年 | 41篇 |
1994年 | 28篇 |
1993年 | 28篇 |
1992年 | 28篇 |
1991年 | 16篇 |
1990年 | 14篇 |
1989年 | 10篇 |
1988年 | 24篇 |
1987年 | 14篇 |
1986年 | 11篇 |
1985年 | 5篇 |
1984年 | 6篇 |
1983年 | 10篇 |
1982年 | 6篇 |
1981年 | 6篇 |
1980年 | 3篇 |
1979年 | 2篇 |
1977年 | 2篇 |
1970年 | 1篇 |
1965年 | 1篇 |
1871年 | 1篇 |
排序方式: 共有7669条查询结果,搜索用时 0 毫秒
51.
Lori Bonertz 《Inpharma》1994,919(1):7-7
The high cost of some newer drugs will have to be justified by significant clinical improvements. However, not all new drugs are more expensive than older options. These are just some of the findings from a cost analysis of antifungal therapy presented at the International Summit on Cutaneous Antifungal Therapy held in San Francisco late last year. Although preliminary, it has provided a first attempt at comparing costs in a therapeutic area practically devoid of published pharmacoeconomic studies. 相似文献
52.
53.
54.
55.
Lori E Shapiro Sandra R Knowles Elizabeth Weber Manuela G Neuman Neil H Shear 《Drug safety》2003,26(3):187-195
OBJECTIVE: To evaluate cross reactivity between sulfonamide antimicrobials and celecoxib in patients with histories of allergies to sulfonamide antimicrobials. METHODS: Immunocompetent patients with a history of sulfonamide antimicrobial allergy who were being considered for therapy with celecoxib were prospectively enrolled. Sulfamethoxazole and trimethoprim skin prick and intradermal testing and/or an in vitro lymphocyte toxicity assay were performed. If skin testing was negative, an oral challenge with sulfamethoxazole and trimethoprim was performed. Oral challenges with celecoxib were administered to all patients. RESULTS: Twenty-eight immunocompetent patients (26 female; mean age 60 years) were evaluated. History of sulfonamide antimicrobial allergy included urticaria (n = 7), cutaneous eruptions (n = 9), and other (n = 12). Four of the 28 patients who were skin prick tested were positive to sulfamethoxazole and two of the ten patients who underwent in vitro testing were positive to sulfamethoxazole. All 28 patients were administered celecoxib and tolerated the medication. Phone call follow up in 25 patients disclosed that 15 patients continued to take celecoxib, while five patients did not take celecoxib following the oral challenge, and five discontinued celecoxib due to adverse effects, lack of drug efficacy or physician preference. CONCLUSIONS: Confusion exists regarding the potential for cross reactivity between sulfonamide antimicrobials and other sulfonamide-containing compounds. The six sulfonamide-allergic patients tolerated celecoxib uneventfully. This pilot study supports the hypothesis that the potential for cross-reactivity between celecoxib and sulfonamide antimicrobials appears to be low. However, further investigations are required to confirm this. 相似文献
56.
Dale Miles Tarak D. Mody Lori I. Hatcher John Fiene Mark Stiles Patrick P. Lin J. W. Lee 《The AAPS journal》2003,5(3):1-16
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) and inductively coupled plasma-atomic emission spectroscopy (ICP-AES) methods were developed and validated for the evaluation of motexafin lutetium (MLu, lutetium texaphyrin, PCI-0123) pharmacokinetics in human plasma. The LC-MS/MS method was specific for MLu, whereas the ICP-AES method measured total elemental lutetium. Both methods were fast, simple, precise, and accurate. For the LC-MS/MS method, a closely related analogue (PCI-0353) was used as the internal standard (IS). MLu and the IS were extracted from plasma by protein precipitation and injected onto and LC-MS/MS system configured with a C18 column and an electrospray interface. The lower limit of quantitation was 0.05 μg MLu mL−1, with a signal-to-noise ratio of 15∶1. The response was linear from 0.05 to 5.0 μg MLu mL−1. For the ICP-AES method, indium was used as the IS. The sample was digested with nitric acid, diluted, filtered, and then injected onto the ICP-AES system. Two standard curve ranges were validated to meet the expected range of sample concentrations: 0.5 to 50, and 0.1 to 10 μg Lu mL−1. The LC-MS/MS and ICP-AES methods were validated to establish accuracy, precision, analyte stability, and assay robustness. Interday precision and accuracy of quality control samples were ≤6.3% coefficient of variation (CV) and within 2.2% relative error (RE) for the LC-MS/MS method, and ≤8.7% CV and within 4.9% RE for the ICP-AES method. Plasma samples from a subset of patients in a clinical study were analyzed using both methods. For a representative patient, over 90% of the elemental lutetium in plasma could be ascribed to intact MLu at early time points. This percentage decreased to 59% at 48 hours after dosing, suggesting that some degradation and/or metabolism of the drug may have occurred. 相似文献
57.
Deborah P Waber Lewis B Silverman Lori Catania William Mautz Montse Rue Richard D Gelber Donna E Levy Meredith A Goldwasser Heather Adams Annie Dufresne Victoria Metzger Ivonne Romero Nancy J Tarbell Virginia Kimball Dalton Stephen E Sallan 《Journal of clinical oncology》2004,22(13):2701-2707
PURPOSE: We evaluated 8-year survival and late neuropsychologic toxicity in children with acute lymphoblastic leukemia treated in a randomized clinical trial to test whether hyperfractionated (twice daily) cranial radiation therapy (CRT) can reduce incidence and severity of late toxicities associated with 18 Gy of CRT. PATIENTS AND METHODS: Between 1987 and 1995, 369 children treated on two consecutive Dana-Farber Cancer Institute Consortium protocols for high-risk acute lymphoblastic leukemia were randomly assigned to conventionally fractionated CRT (CFX) or hyperfractionated CRT (HFX) to a total dose of 18 Gy. Neuropsychologic testing was completed for 125 of 287 children in continuous complete remission. Event-free and overall survival, as well as neuropsychologic function, were compared for the two arms of the protocol. RESULTS: Eight-year event-free survival (+/- SE) was 80% +/- 3% for children randomly assigned to CFX and 72% +/- 3% for HFX (P =.06). Overall survival was 85% +/- 3% for CFX and 78% +/- 3% for HFX (P =.06). CNS relapses occurred in 2.8% of patients receiving CFX and 2.7% receiving HFX (P =.99). Cognitive function for both groups was solidly in the average range, with no group differences in intelligence, academic achievement, visuospatial reasoning, or verbal learning. Children on the HFX arm exhibited a modest advantage for visual memory (P <.05). CONCLUSION: HFX provides no benefit in terms of cognitive late effects and may compromise antileukemic efficacy. HFX should not be substituted for conventionally dosed CRT in children who require radiation therapy for treatment of acute lymphoblastic leukemia. 相似文献
58.
George V Thomas Steve Horvath Bradley L Smith Katherine Crosby Lori A Lebel Matthew Schrage Jonathan Said Jean De Kernion Robert E Reiter Charles L Sawyers 《Clinical cancer research》2004,10(24):8351-8356
PURPOSE: As kinase inhibitors transition from the laboratory to patients, it is imperative to develop biomarkers that can be used in the clinic. The primary objectives are to identify patients most likely to benefit from molecularly targeted therapies and to document modulation of the drug target. Constitutive activation of the phosphoinositide 3-kinase (PI3K) pathway and its downstream effectors, as a result of PTEN loss or by other mechanisms, occurs in a high proportion of prostate cancers, making it an ideal template for the design of clinical trials involving PI3K pathway inhibitors. Prostate cancers also present unique organ-specific challenges, in that tumors are heterogeneous and diagnostic tissue is extremely limited. EXPERIMENTAL DESIGN: Working within these limitations, we have developed a set of immunohistochemical assays that define activation of the PI3K pathway in clinical samples. Results and CONCLUSIONS: Using both univariate and multivariate analyses, we show that loss of PTEN is highly correlated with the activation of AKT, and this, in turn, is associated with the phosphorylation of S6, one of its main effectors. These three antibodies are potentially able to define a molecular signature of PTEN loss and/or AKT pathway activation in prostate cancer. 相似文献
59.
Edward Chow Lori Holden Joel Rubenstein Monique Christakis Katharina Sixel Marjan Vidmar Joel Finkelstein Charles Hayter Andrew Loblaw Rebecca Wong Ewa Szumacher Cyril Danjoux 《Radiotherapy and oncology》2004,70(3):291-294
Twenty-five patients with osteolytic metastases had computed tomography (CT) scans before and 3 months after palliative radiotherapy. The median % density change following single 8 Gy, 20 Gy/5#, 30 Gy/10# were: 128 (range 98–255), 141 (79–342), and 145 (65–235), respectively. It is feasible to evaluate remineralization of osteolytic lesions with palliative radiotherapy. 相似文献
60.
Serologic evidence of human papillomavirus 16 and 18 infections and risk of prostate cancer. 总被引:2,自引:0,他引:2
Karin A Rosenblatt Joseph J Carter Lori M Iwasaki Denise A Galloway Janet L Stanford 《Cancer epidemiology, biomarkers & prevention》2003,12(8):763-768
Human papillomavirus (HPV) subtypes 16 and 18 are sexually transmitted and have been associated with an increased incidence of several anogenital tumors. Although previous epidemiological studies have suggested that sexual behaviors such as an early age at first intercourse and larger numbers of sexual partners are also related to an increased risk of prostate cancer, seroepidemiological studies of these infectious agents in relation to prostate cancer have produced differing results. To further evaluate this potential relationship, we completed a population-based control study in King County, Washington. Middle-aged (40-64 years) men diagnosed with prostate cancer (n = 642) were ascertained through the Seattle-Puget Sound Surveillance, Epidemiology, and End Results cancer registry between January 1993 and December 1996. Controls (n = 570) of similar age were selected from the same population as the cases by random digit dialing. Overall, there was no association between serological evidence of prior HPV-16 (adjusted odds ratio, 1.06; 95% confidence interval, 0.71-1.57) or HPV-18 (adjusted odds ratio, 1.36; 95% confidence interval, 0.69-2.69) infection and the risk of prostate cancer. Analyses of clinical features demonstrated no relationship between HPV infection status and Gleason score, stage of disease, or a combined measure of disease aggressiveness. Our findings indicate that HPV-16 and HPV-18 are not associated with prostate cancer risk. 相似文献